Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of AFQ056 in PD-LID Extension Study
NCT01173731Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2010
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of mavoglurant in levodopa-induced dyskinesia (LID), sponsored by Novartis. Primary endpoint: Incidence and severity of AEs/SAEs at 3.5 years. Started Oct 2010; status: completed.
02
Drugs
mavoglurant
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT01173731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01173731.